If one looks at corporate announcements, a large number of small and mid-caps pharma companies are announcing one or the other thing either about US FDA or European authorities giving approval or inspection. While the large players had moved to international markets a long time back, a number of small companies that had domestic focussed business are also moving into the developed global markets. Will this lead to re-rating?
Murphy USA Inc. (NYSE:MUSA) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Thank you for standing by. My name is Kayla Baker, and I will be your conference operator today. At this time, I’d like to welcome everyone to the Murphy USA Third Quarter 2023 Earnings Conference Call. All lines have been placed on […]
Nu Skin Enterprises, Inc. (NYSE:NUS) Q3 2023 Earnings Call Transcript November 1, 2023 Nu Skin Enterprises, Inc. misses on earnings expectations. Reported EPS is $-0.74 EPS, expectations were $0.65. Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to Nu Skin Enterprises’ Third Quarter 2023 Earnings Conference Call. At this time, all […]
"The BFSI space has held up well. Midcap IT has produced another quarter of stupendous earnings and management commentaries are pointing out towards no damage to probably come from either the pricing action or demand dynamics at least at this juncture. A few of the capital good companies obviously have reported a strong set of numbers and though cement companies have disappointed, the reason is obvious. Q2 is expected to be weak for monsoons."